ReviewAsian journal of pharmaceutical sciences2023

Research progress and application of the CRISPR/Cas9 gene-editing technology based on hepatocellular carcinoma.

Shijing Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.